Alamar Biosciences, Inc.
NASDAQ:ALMRBiotechnology
+$1.11 today
- Market cap
- $2.12B
- Beta
- 0.00
- P/E (TTM)
- -47.5
- EPS (TTM)
- -$0.45
Volume 0.53M
Average 0.38M
ALMR Total Liabilities
Everything the company owes to creditors and other parties.
Alamar Biosciences, Inc.NASDAQ: ALMR
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities of $78.12M in Q2 FY2026
Q2 FY2026 total liabilities was $78.12M.
Context
- Total liabilities amounted to 20.0% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 298.95M USD
- Year-over-year change
- +5.7%
- 1-year CAGR
- +5.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 298.95M | +5.7% |
| FY2024 | 2024-12-31 | 282.92M | — |
Total Liabilities vs competitors
How ALMR compares with its peers on the latest reported figures
- ALMR's Jun 2026 total liabilities of $78.12M is the 5th highest of the 9 companies compared; the peer median is $151.54M.
- Total liabilities amounts to 20.0% of total assets for ALMR, versus a peer median of 18.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $780M | +1.4% | -13.5% | 99.7% | |
| Sep 2026 | $471.13M | -15.9% | -5.3% | 17.9% | |
| Sep 2026 | $233.79M | +38.4% | +15.2% | 20.8% | |
| Sep 2026 | $225.09M | -7.1% | +3.2% | 21.2% | |
ALMRAlamar Biosciences, Inc. | Jun 2026 | $78.12M | — | — | 20.0% |
| Mar 2026 | $77.99M | -37.6% | -32.8% | 12.2% | |
| Mar 2026 | $33.36M | +0.3% | -0.9% | 18.8% | |
| Mar 2026 | $30.65M | -15.5% | -3.5% | 11.3% | |
| Mar 2026 | $12.6M | -48.1% | -8.2% | 5.9% | |
| Peer median (excluding ALMR) | $151.54M | -11.3% | -4.4% | 18.3% | |
Competitors are the stored peer set for ALMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 26.77M | 30M |
| Short-term Investments | 52.59M | 0 |
| Net Receivables | 7.32M | 12.75M |
| Inventory | 14.41M | 38.48M |
| Other Current Assets | 5.61M | 13.47M |
| Total Current Assets | 106.7M | 94.71M |
| Property, Plant & Equipment (Net) | 35.1M | 36.63M |
| Goodwill | 0 | 0 |
| Intangible Assets | 2.04M | 1.99M |
| Long-term Investments | 0 | 0 |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 5.67M | 6.67M |
| Total Non-current Assets | 42.81M | 45.29M |
| Total Assets | 149.51M | 139.99M |
| Account Payables | 6.19M | 5.87M |
| Short-term Debt | 0 | 0 |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 575K | 470K |
| Other Current Liabilities | 5.42M | 7.59M |
| Total Current Liabilities | 16.59M | 23.73M |
| Long-term Debt | 0 | 9.81M |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 235.14M | 235.84M |
| Total Non-current Liabilities | 266.33M | 275.22M |
| Total Liabilities | 282.92M | 298.95M |
| Common Stock | 1K | 1K |
| Retained Earnings | (138.96M) | (168.78M) |
| Accumulated OCI | 149K | (72K) |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | (133.41M) | (158.95M) |
| Total Debt | 33.1M | 41.47M |
| Net Debt | 6.33M | 11.47M |
Alamar Biosciences, Inc.
NASDAQ:ALMR
Intrinsic Alpha fair value
Locked
Current Price
$30.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.